facebook button LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash

Sponsor: Lutris Pharma Ltd.

Protocol L-02-01: Protocol L-02-01: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.

Topical treatment for patients who experience acneiform rash after beginning anti-cancer treatment with a regimen including either cetuximab or panitumumab.

For more information contact the research department at 631-675-5075